RE: For the win9 Apr 2018 21:51
We should always respect alternate views - Midas has said nothing but the truth, that a significant portion of the market cap is speculative.
Back when Aphria was double the price, FFWD looked like a bargain, but never mind. Aphria is a low cost producer, and in a highly competitive market I think they can beat the competition, but it's still a risky business and we don't know who will come out on top.
Intensity sounds fantastic but there has been many promising cancer drugs that have failed at phase 3, so it's not one to rely on. With Yooya it's difficult to know what's going on, but they don't have to become a huge company for us to make a lot of money from them as we hold 15%.
Factom's the pick of the bunch imo. Could become a world leader. Could also fail completely of course. This type of investing is inherently risky.